Literature DB >> 3278783

Chronic obstructive pulmonary disease.

N R Anthonisen1.   

Abstract

Outpatient management of chronic obstructive pulmonary disease (COPD) is reviewed in this paper. Smoking cessation is probably important, although its benefit in established COPD is unproven. Bronchodilator therapy may be of more than symptomatic benefit and is indicated in virtually all patients. Specific beta 2-agonists are the most widely used agents and can be given in substantially larger doses than are usually recommended. Ipratropium bromide, an anticholinergic drug, is about as effective as a beta 2-agonist, but in large doses the two drugs do not seem to have additive effects, unlike theophylline and beta 2-agonists. Systemic corticosteroids decrease airway obstruction substantially in a small number of patients with COPD; these agents should be reserved for these patients and used sparingly. Inhaled steroids are of little benefit, as are respiratory stimulants and depressants. Broad-spectrum antibiotic therapy helps to relieve symptomatic exacerbations of COPD, particularly those characterized by increased dyspnea, sputum volume and sputum purulence. Cor pulmonale is best managed by diuretics and oxygen, with digoxin reserved for left ventricular failure and supraventricular arrhythmias. Continuous oxygen therapy at home is indicated for the patients who have chronic arterial hypoxemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278783      PMCID: PMC1267696     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  46 in total

1.  Sch 1000: a new anticholinergic bronchodilator.

Authors:  M J Gross
Journal:  Am Rev Respir Dis       Date:  1975-12

2.  Factors affecting the decline of FEV1 in chronic bronchitis.

Authors:  C E Barter; A H Campbell; M K Tandon
Journal:  Aust N Z J Med       Date:  1974-08

3.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

4.  Cardiac toxicity of aerosol propellants.

Authors:  A Silverglade
Journal:  JAMA       Date:  1972-11-13       Impact factor: 56.272

5.  Antibody response to inactivated influenza vaccine given by different routes in patients with chronic bronchopulmonary disease.

Authors:  S L Shore; C W Potter; C H Stuart-Harris
Journal:  Thorax       Date:  1973-11       Impact factor: 9.139

6.  The clinical pharmacology of oral and inhaled salbutamol.

Authors:  S R Walker; M E Evans; A J Richards; J W Paterson
Journal:  Clin Pharmacol Ther       Date:  1972 Nov-Dec       Impact factor: 6.875

Review 7.  Role of infection in chronic bronchitis.

Authors:  I Tager; F E Speizer
Journal:  N Engl J Med       Date:  1975-03-13       Impact factor: 91.245

8.  Theophylline-induced seizures in adults. Correlation with serum concentrations.

Authors:  C W Zwillich; F D Sutton; T A Neff; W M Cohn; R A Matthay; M M Weinberger
Journal:  Ann Intern Med       Date:  1975-06       Impact factor: 25.391

9.  Chronic bronchitis: a 10-year follow-up.

Authors:  N C Oswald; V C Medvei; R E Waller
Journal:  Thorax       Date:  1967-05       Impact factor: 9.139

10.  Comparative trial of a new anticholinergic bronchodilator, Sch 1000, and salbutamol in chronic bronchitis.

Authors:  H Poppius; Y Salorinne
Journal:  Br Med J       Date:  1973-10-20
View more
  1 in total

1.  Co-morbid disease in COPD--more than a coincidence.

Authors:  Alan J Crockett; David Price
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.